Advertisement
Advertisement

More Related Content

Slideshows for you(20)

Similar to Medicines Manufacturing Challenge EDI Survey Briefing Webinar(20)

Advertisement

More from KTN(20)

Advertisement

Medicines Manufacturing Challenge EDI Survey Briefing Webinar

  1. www.ktn-uk.org Medicines Manufacturing Challenge EDI Survey Briefing Webinar Friday 12th November 2021 Medicines Manufacturing Challenge Community
  2. Agenda Time Topic Presenter 11:00 - 11:05 Welcome and introduction Karen Wilkinson (Medicines Manufacturing Lead, KTN) 11:05 - 11:15 Overview of Innovate UK’s EDI Strategy and Vision Katy Petherick, Equality, Diversity and Inclusion Programme Lead (Embedding), Innovate UK 11:15 - 11:30 Medicines Manufacturing EDI Survey Pav Tiwana (Programme Manager, Medicines Manufacturing Challenge, Innovate UK) Alex Bacon (Workplace Inclusion Coordinator, Diversity and Ability) 11.30-11.45 Panel Q&A Katy Petherick, Pav Tiwana, Alex Bacon, Andreea Iftimia-Mander (Innovation Lead Medicines Manufacturing Challenge) 11:30 - 11:45 Survey Pav Tiwana 11:55 Close Karen Wilkinson
  3. Inclusive Innovation Katy Petherick EDI Programme Lead
  4. At Innovate UK, we are committed to encouraging diversity and inclusion in business innovation
  5. § The best ideas for innovation can come from anyone - to access the full talent available across the UK we need to increase the visibility and accessibility of our support. § Diversity within businesses is proven to contribute to enhanced performance and commercial success and we can help businesses to benefit from this. § If we encourage businesses to consider diversity and inclusion in their approach to innovation the economic and societal impacts that are delivered through our programmes will be maximised. Why?
  6. £2 billion a month is lost by UK businesses by ignoring the needs of disabled people wearepurple.org.uk Companies whose executive teams are in the top quartile for gender diversity are more likely to financially outperform their peers. For ethnic diversity, this rises to 36% 25% McKinsey and Company; Diversity Wins Ethnic minority-led firms in the UK are more likely to have engaged in product or service and more likely to export innovation Federation of Small Businesses (FSB) UK; Unlocking Opportunity
  7. What are the consequences of exclusion?
  8. We need an Innovation ecosystem that provides solutions for all
  9. diverse We must increase the diversity of upcoming innovation talent and make innovation support more visible, accessible, and inclusive to all. § Targeted Programmes (Women in Innovation, Young Innovators) § Increase community engagement § Develop application process & policies § Improve support for applicants § Internal recruitment
  10. We will support innovative companies to fully understand the value of EDI and build it into their innovation and growth strategies § Innovate UK People strategy to have core EDI strand § EDI Advocates across Innovate UK § Enable sharing of good practice § Provide EDI-related business advice via Innovate UK EDGE inclusive
  11. We will encourage companies to develop products and services with a focus on inclusive innovation § Update application process to support planning of EDI in innovation § Upskilling Assessors and Monitoring Officers § Inclusive Design toolkit to support planning of EDI in innovation embedded
  12. We need good data to target action in the right places and monitor impacts and progress § Updating EDI survey questions and collection method § Extend Ventures analysis of historical applicants § Build new evidence and insights § Collaborate across the innovation ecosystem effective
  13. diverse inclusive embedded effective
  14. Understanding the Medicines Manufacturing and Digital Heath Technology Catalyst (DHTC) funded portfolio’s protected characteristics Equality, Diversity & Inclusion (EDI) Survey
  15. Pav Tiwana – Programme Manager, ISCF Medicines Manufacturing Challenge, Innovate UK Alex Bacon – Workplace Inclusion Coordinator, Diversity and Ability (D&A) Introductions
  16. We are running a survey to capture the protected characteristics of those involved in the project teams. We would like to understand the type of people working on projects we have funded as part of the Medicines Manufacturing and Digital Health Technology Catalyst (DHTC) competitions. This is wider than project leads or exec team members. From finance business partners to technicians allocated to this project. Including closed and currently live projects. The ask We’ll be sending you (as project leads) an email with more information and a link to the survey: • Complete the survey for yourself • Share this email with those who are/were a part of your project team What are we doing?
  17. 1. All ISCF Challenges are completing a similar exercise, with D&A analysing the results to product a report with recommendations and findings. 2. An EDI strategy for medicines manufacturing sector and Innovate UK – baseline will help us understand who we’re currently attracting. 3. Building an EDI community for medicines manufacturing. What are the expected outputs?
  18. • To understand who we’re funding: Identify which protected characteristic groups we are attracting / are missing. • Identify potential focus areas as we develop our EDI strategy for medicines manufacturing sector – next steps and engagement plan. • Help identify perceived gaps and improvements to UKRI/IUK processes. • Start engaging with communities we are not funding to understand how we can support them including reviewing our policies e.g. is our language inclusive? • Once we have implemented changes, we would like to see with the next set of funded projects whether the barriers we are aiming to remove are having the desired effect. Why do we need a baseline?
  19. • The survey is focused on understanding the protected characteristics of those involved in projects we’ve funded. • The protected characteristics included in the survey: • The questions are based on ONS EDI protected characteristics. • We're only asking questions where we can act on the data. We’ve removed any unnecessary questions e.g. marital status • To help with our analysis, we will be asking: o Challenge(s) you were funded by – please select any of the ISCF Challenges you were funded by (only need to complete survey once) o Organisation size and type About the survey Social economic Sexual orientation Ethnicity Disability Religion
  20. Share your views: You also have the option to share your views on how well the sector is doing in encouraging the EDI agenda, challenges and potential solutions. Get involved! We will also be sending a link to opt into more EDI activities, and join our growing EDI medicines manufacturing community where we share learnings. Opt out: You have the option to opt out of completing the survey. Please can you still share with your project team members. About the survey
  21. Data handling • All data will be handled by D&A to analyse, produce the final report, and then the data will be given to UKRI to handle. After the report has been created, D&A will not store the data or have access to it. • The survey is hosted on Survey Monkey, is anonymous and all data is non-identifiable. • The role of D&A is to: o Handle the survey and incoming data o Gather data on EDI within each challenge area o Analyse the data and produce a final comprehensive report o During this time, be the point of contact for UKRI and any queries relating to the survey • D&A will conduct interviews to garner qualitative data for the report, from those who would like to be involved. Alias will be created and data gathered from this will be with individual consent from each participant.
  22. • We will use the data to inform the report and build on the responses we have received in the initial pilot phase • The data will be used to assess the current situation of EDI statistics within ISCF funded projects • The data will be analysed by D&A’s research team with an intersectional approach in mind • The report will be sent to EDI Advocates and Challenge Leads for baseline The data will not used for any other purposes. How the survey data will and will not be used
  23. Pilot: What does the data tell us?
  24. Pilot: What does the data tell us?
  25. What are we going to do with the information? • D&A will assess the current situation of EDI statistics within ISCF Challenges, and create a final report. • The data will be leading the way in identifying which protected characteristic groups we are attracting. • Start engaging with communities we are not funding to understand how we can support them by removing barriers, starting with reviewing our internal policies and processes. • Contextualising the baseline against available industry level data. • As part of our EDI strategy, this data will help inform our next steps and engagement plan. How will this data help inform our actions?
  26. How will supplying this data help you? • EDI will underpin all future funding for IUK. This information will ensure we're doing the right thing. • Working in innovation, there is a need and benefit to working in a diverse team – influence the sector to change work cultures, talent and skills programmes • We’re reviewing our internal processes to be as assessable as possible. • We’re building an EDI community within Medicines Manufacturing – addressing challenges with potential solutions and sharing learnings. • Opportunity to use the same survey to gather your organisations EDI data as well. How will this data help inform our actions?
  27. The ask We’ll be sending you (as project leads) an email with more information and a link to the survey: • Complete the survey for yourself • Share this email with those who are/were a part of your project team You will receive: • Link to the survey • Survey participants information sheet • List of ISCF Challenges, including competition names so you can identify if you’ve been funded by more than one ISCF Challenge • Link to register your interest in getting more involved with EDI at Innovate UK/D&A/Medicines Manufacturing Challenge • Link to opt out of filling in this survey Queries – direct them to KTN or D&A Next Steps
  28. Panel Q&A
  29. Survey
  30. www.ktn-uk.org Thankyou! karen.wilkinson@ktn-uk.org pavan.tiwana@innovateuk.ukri.org Medicines Manufacturing Challenge Community: https://ktn-uk.org/programme/medicines-manufacturing-challenge-community/
Advertisement